New insights into lipid metabolism and prostate cancer (Review)
暂无分享,去创建一个
Zhihua Tao | Yiwen Sang | Xiuzhi Duan | Weiwei Liu | P. Kong | Kangle Feng | Chunhua Liu | Weixi Wang | Zhengliang Zhang | Tao Sun
[1] L. Horvath,et al. Targeting lipid metabolism in metastatic prostate cancer , 2023, Therapeutic advances in medical oncology.
[2] Zhaoqi Zhang,et al. FABP5 controls macrophage alternative activation and allergic asthma by selectively programming long-chain unsaturated fatty acid metabolism. , 2022, Cell reports.
[3] M. Stockler,et al. Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin , 2022, Cancers.
[4] M. Ediriweera. Use of cholesterol metabolism for anti-cancer strategies. , 2022, Drug discovery today.
[5] F. Saad,et al. Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up , 2022, Cancers.
[6] Wei Xue,et al. Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer. , 2022, Cancer research.
[7] A. Patnaik,et al. Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer , 2022, bioRxiv.
[8] Hui Zhang,et al. ELOVL2 restrains cell proliferation, migration, and invasion of prostate cancer via regulation of the tumor suppressor INPP4B. , 2022, Cellular signalling.
[9] J. Carles,et al. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER , 2022, European journal of cancer.
[10] F. Brimo,et al. Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients , 2022, Oncogene.
[11] N. Pavlova,et al. The hallmarks of cancer metabolism: Still emerging. , 2022, Cell metabolism.
[12] R. Schwabe,et al. Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis. , 2022, Journal of hepatology.
[13] J. Pardo,et al. Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer , 2022, Nutrients.
[14] Jordan F Hastings,et al. Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover , 2022, Cancer & Metabolism.
[15] Stephen L. Pinkosky,et al. Lipogenesis inhibitors: therapeutic opportunities and challenges , 2022, Nature Reviews Drug Discovery.
[16] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[17] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[18] A. Ziegler,et al. A hormone complex of FABP4 and nucleoside kinases regulates islet function , 2021, Nature.
[19] Hongqiang Cheng,et al. Oxidative stress-induced FABP5 S-glutathionylation protects against acute lung injury by suppressing inflammation in macrophages , 2021, Nature Communications.
[20] C. Cordon-Cardo,et al. MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. , 2021, Cancer letters.
[21] Guan-Jhong Huang,et al. Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1/FASN-driven metabolism and AR. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[22] M. Cox,et al. Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer , 2021, Pharmaceutics.
[23] Yi Sun,et al. ELOVL5-Mediated Long Chain Fatty Acid Elongation Contributes to Enzalutamide Resistance of Prostate Cancer , 2021, Cancers.
[24] R. Oliart-Ros,et al. Inhibition of Stearoyl-CoA Desaturase by Sterculic Oil Reduces Proliferation and Induces Apoptosis in Prostate Cancer Cell Lines , 2021, Nutrition and cancer.
[25] I. Csizmadi,et al. Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer , 2021, The Journal of urology.
[26] F. Bruyère,et al. Lipophagy and prostate cancer: association with disease aggressiveness and proximity to periprostatic adipose tissue , 2021, The Journal of pathology.
[27] V. Zuber,et al. The relationship between Lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. , 2021, medRxiv.
[28] B. Staels,et al. PPAR control of metabolism and cardiovascular functions , 2021, Nature Reviews Cardiology.
[29] R. Gillies,et al. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer , 2021, Cancer Research.
[30] M. Loda,et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer , 2021, Cancer Research.
[31] Yanqing Wang,et al. HOXD13 suppresses prostate cancer metastasis and BMP4‐induced epithelial‐mesenchymal transition by inhibiting SMAD1 , 2021, International journal of cancer.
[32] Yuan Liu,et al. Knockdown of sterol O-acyltransferase 1 (SOAT1) suppresses SCD1-mediated lipogenesis and cancer procession in prostate cancer. , 2021, Prostaglandins & other lipid mediators.
[33] R. Godbout,et al. An Amplified Fatty Acid-Binding Protein Gene Cluster in Prostate Cancer: Emerging Roles in Lipid Metabolism and Metastasis , 2020, Cancers.
[34] C. Thaxton,et al. Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol‐dependent manner , 2020, Journal of extracellular vesicles.
[35] A. Scott,et al. Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. , 2020, Nuclear medicine and biology.
[36] E. Lerma,et al. LDL, HDL and endocrine-related cancer: from pathogenic mechanisms to therapies. , 2020, Seminars in cancer biology.
[37] C. Thompson,et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis , 2020, Proceedings of the National Academy of Sciences.
[38] J. Kench,et al. Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition , 2020, Cancer Research.
[39] Xianming Deng,et al. Blocking PPARγ interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression , 2020, Proceedings of the National Academy of Sciences.
[40] R. Godbout,et al. The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelial‐to‐mesenchymal transition and lipid‐derived energy production in prostate cancer cells , 2020, Molecular oncology.
[41] R. Mancini,et al. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition , 2020, Journal of experimental & clinical cancer research : CR.
[42] M. Kaczocha,et al. FABP5 as a novel molecular target in prostate cancer. , 2020, Drug discovery today.
[43] W. Wahli,et al. GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK. , 2020, Cell reports.
[44] E. Sauter,et al. SnapShot: FABP Functions , 2020, Cell.
[45] B. Dai,et al. Targeting CPT1B as a potential therapeutic strategy in castration‐resistant and enzalutamide‐resistant prostate cancer , 2020, The Prostate.
[46] Giovanny Rodriguez Blanco,et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer , 2020, Nature Communications.
[47] Hong-xia Li,et al. GPR120 facilitates cholesterol efflux in macrophages through activation of AMPK signaling pathway , 2020, The FEBS journal.
[48] Xiaoxuan Liu,et al. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[49] A. Harraz,et al. Evaluation of serum fatty acid binding protein-4 (FABP-4) as a novel biomarker to predict biopsy outcomes in prostate biopsy naïve patients , 2020, International Urology and Nephrology.
[50] M. Loda,et al. Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases , 2020, Oncogene.
[51] J. Turkson,et al. 27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6–JAK–STAT3 Signaling in Prostate Cancer Cells , 2020, Molecular Cancer Research.
[52] M. Gomaraschi. Role of Lipoproteins in the Microenvironment of Hormone-Dependent Cancers , 2019, Trends in Endocrinology & Metabolism.
[53] M. Kaczocha,et al. FABP5 coordinates lipid signaling that promotes prostate cancer metastasis , 2019, Scientific Reports.
[54] L. Trotman,et al. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth , 2019, The Prostate.
[55] Bart W. J. Philips,et al. A multitransmit external body array combined with a 1H and 31P endorectal coil to enable a multiparametric and multimetabolic MRI examination of the prostate at 7T , 2019, Medical physics.
[56] G. Wang,et al. Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer. , 2019, Cancer research.
[57] Shan Gao,et al. Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP. , 2019, Cancer research.
[58] A. Scorilas,et al. Molecular characterization, genomic structure and expression analysis of a gene (CATL1/CPT1C) encoding a third member of the human carnitine acyltransferase family. , 2019, Genomics.
[59] V. Giri,et al. Diet assessment among men undergoing genetic counseling and genetic testing for inherited prostate cancer: Exploring a teachable moment to support diet intervention , 2019, The Prostate.
[60] M. D. De Velasco,et al. HOXA10 expression profiling in prostate cancer , 2019, The Prostate.
[61] K. Taari,et al. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study , 2019, Prostate cancer and prostatic diseases.
[62] L. Fazli,et al. Roles of the HOXA10 gene during castrate-resistant prostate cancer progression. , 2019, Endocrine-related cancer.
[63] Elizabeth C. Randall,et al. Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging , 2019, Molecular Cancer Research.
[64] D. Sabatini,et al. Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death , 2019, Nature.
[65] D. Nomura,et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer , 2019, Science Translational Medicine.
[66] P. Muti,et al. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. , 2019, Cell metabolism.
[67] M. Loda,et al. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer , 2018, Proceedings of the National Academy of Sciences.
[68] K. Gardner,et al. CTBP1/CYP19A1/estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome , 2018, International journal of cancer.
[69] A. Esnakula,et al. Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men , 2018, The Prostate.
[70] H. Stahlberg,et al. Structural basis for regulation of human acetyl-CoA carboxylase , 2018, Nature.
[71] Shuyan Liu,et al. SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis. , 2018, Cancer letters.
[72] S. Raimondo,et al. Label-free quantitative proteomic profiling of colon cancer cells identifies acetyl-CoA carboxylase alpha as antitumor target of Citrus limon-derived nanovesicles. , 2018, Journal of proteomics.
[73] F. Kraemer,et al. SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux. , 2018, Annual review of physiology.
[74] D. Ford,et al. Phospholipid Remodeling and Cholesterol Availability Regulate Intestinal Stemness and Tumorigenesis. , 2018, Cell stem cell.
[75] J. Clohessy,et al. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer , 2018, Nature Genetics.
[76] I. Mills,et al. Genetics of lipid metabolism in prostate cancer , 2018, Nature Genetics.
[77] Kshitij Srivastava,et al. Acetyl-CoA Carboxylase 1-Dependent Protein Acetylation Controls Breast Cancer Metastasis and Recurrence. , 2017, Cell metabolism.
[78] M. Stockler,et al. A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer , 2017, International Journal of Cancer.
[79] K. Takayama,et al. ACSL3 promotes intratumoral steroidogenesis in prostate cancer cells , 2017, Cancer science.
[80] S. S. Kanwar,et al. Phosphatidylserine: A cancer cell targeting biomarker. , 2017, Seminars in cancer biology.
[81] William A. Flavahan,et al. Epigenetic plasticity and the hallmarks of cancer , 2017, Science.
[82] H. Han,et al. BNIP3 induction by hypoxia stimulates FASN-dependent free fatty acid production enhancing therapeutic potential of umbilical cord blood-derived human mesenchymal stem cells , 2017, Redox biology.
[83] Jianmin Wang,et al. Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer. , 2017, Cancer letters.
[84] N. Azad,et al. Anti‐Tumorigenic Potential of a Novel Orlistat‐AICAR Combination in Prostate Cancer Cells , 2017, Journal of cellular biochemistry.
[85] V. Parra,et al. Calcium Transport and Signaling in Mitochondria. , 2017, Comprehensive Physiology.
[86] Y. Furuya,et al. Simvastatin Up‐Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen‐Independent Human Prostate Cancer Cells , 2017, The Prostate.
[87] S. Freedland,et al. The current evidence on statin use and prostate cancer prevention: are we there yet? , 2017, Nature Reviews Urology.
[88] Y. Zou,et al. FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1 , 2016, Proceedings of the National Academy of Sciences.
[89] Christian M. Metallo,et al. ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch. , 2016, Cell reports.
[90] Jennifer R. Rider,et al. Cholesterol Metabolism and Prostate Cancer Lethality. , 2016, Cancer research.
[91] B. Stockwell,et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis , 2016, Proceedings of the National Academy of Sciences.
[92] J. Fernandez-Checa,et al. Mitochondria, cholesterol and cancer cell metabolism , 2016, Clinical and Translational Medicine.
[93] L. Arab,et al. Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project , 2016, Prostate Cancer and Prostatic Diseases.
[94] A. Rust,et al. Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer , 2016, Proceedings of the National Academy of Sciences.
[95] Navdeep S. Chandel,et al. Fundamentals of cancer metabolism , 2016, Science Advances.
[96] L. Butler,et al. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. , 2016, Endocrine-related cancer.
[97] J. Locasale,et al. The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.
[98] M. Golzio,et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity , 2016, Nature Communications.
[99] Richard Ventura,et al. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression , 2015, EBioMedicine.
[100] Saumyadipta Pyne,et al. AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. , 2014, Cancer research.
[101] D. Xiao,et al. Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. , 2014, Cancer letters.
[102] S. Langley,et al. Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection , 2014, BJU international.
[103] Zhi-ping Chen,et al. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis , 2014, Journal of Lipid Research.
[104] Ji-Xin Cheng,et al. Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. , 2014, Cell metabolism.
[105] Xiangyan Li,et al. Fatostatin Displays High Antitumor Activity in Prostate Cancer by Blocking SREBP-Regulated Metabolic Pathways and Androgen Receptor Signaling , 2014, Molecular Cancer Therapeutics.
[106] T. Salo,et al. The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas , 2013, Molecular Cancer Therapeutics.
[107] Jayantha B. Tennakoon,et al. Androgens Regulate Prostate Cancer Cell Growth via an AMPK-PGC-1α-Mediated Metabolic Switch , 2013, Oncogene.
[108] S. Freedland,et al. The relationship between nutrition and prostate cancer: is more always better? , 2013, European urology.
[109] Pier Paolo Pandolfi,et al. Cancer metabolism: fatty acid oxidation in the limelight , 2013, Nature Reviews Cancer.
[110] C. Magi-Galluzzi,et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. , 2013, Cancer research.
[111] J. Krycer,et al. A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products. , 2012, The Biochemical journal.
[112] T. Wilt,et al. Statin Use and Risk of Prostate Cancer in the Prospective Osteoporotic Fractures in Men (MrOS) Study , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[113] L. Chung,et al. Activation of Androgen Receptor, Lipogenesis, and Oxidative Stress Converged by SREBP-1 Is Responsible for Regulating Growth and Progression of Prostate Cancer Cells , 2011, Molecular Cancer Research.
[114] G. Mills,et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.
[115] S. Kridel,et al. Polyunsaturated fatty acid metabolism in prostate cancer , 2011, Cancer and Metastasis Reviews.
[116] S. Balk,et al. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. , 2011, Endocrine-related cancer.
[117] M. Freeman,et al. The complex interplay between cholesterol and prostate malignancy. , 2011, The Urologic clinics of North America.
[118] Matej Oresic,et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. , 2011, Cancer research.
[119] F. Hanisch,et al. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer , 2011, Expert review of proteomics.
[120] R. Komoroski,et al. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia , 2011, Magnetic resonance in medicine.
[121] Yuan Yuan Wang,et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. , 2011, Cancer research.
[122] Chawnshang Chang,et al. Stearoyl CoA desaturase (SCD) facilitates proliferation of prostate cancer cells through enhancement of androgen receptor transactivation , 2011, Molecules and cells.
[123] Wendy A Wells,et al. Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation , 2011, Molecular Cancer Therapeutics.
[124] M. Thun,et al. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. , 2010, Cancer research.
[125] K. Solomon,et al. Prohibitin is a cholesterol‐sensitive regulator of cell cycle transit , 2010, Journal of cellular biochemistry.
[126] M. Loda,et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[128] S. Culine,et al. Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice , 2010, Molecular Cancer Therapeutics.
[129] G. Marceau,et al. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells , 2010, Oncogene.
[130] C. Nelson,et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration‐resistant prostate cancer in a mouse xenograft model , 2010, The Prostate.
[131] M. Gleave,et al. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance , 2010, The Prostate.
[132] I. Thompson,et al. Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial , 2009, Cancer Epidemiology, Biomarkers & Prevention.
[133] Yusuke Nakamura,et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. , 2009, Cancer research.
[134] M. Gleave,et al. Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts , 2009, The Journal of Steroid Biochemistry and Molecular Biology.
[135] W. Hahn,et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. , 2009, Journal of the National Cancer Institute.
[136] G. Schwartz,et al. Hypercholesterolemia and prostate cancer: a hospital-based case–control study , 2008, Cancer Causes & Control.
[137] J. Storch,et al. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. , 2008, Annual review of nutrition.
[138] E. Rimm,et al. Statin drugs and risk of advanced prostate cancer. , 2006, Journal of the National Cancer Institute.
[139] Y. Liu,et al. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.
[140] W. Welshons,et al. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer , 2006, Molecular and Cellular Endocrinology.
[141] K. T. Patton,et al. Decreased annexin I expression in prostatic adenocarcinoma and in high‐grade prostatic intraepithelial neoplasia , 2005, Histopathology.
[142] M. Freeman,et al. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer , 2005, Trends in Endocrinology & Metabolism.
[143] F. Ichas,et al. Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment , 2005, Molecular and Cellular Biology.
[144] J. Menéndez,et al. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[145] Jayoung Kim,et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. , 2005, The Journal of clinical investigation.
[146] P. Febbo,et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. , 2003, Molecular cancer research : MCR.
[147] P. Rudland,et al. High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity , 2003, Oncogene.
[148] M. Freeman,et al. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. , 2002, Cancer research.
[149] E. Ikonen,et al. How cells handle cholesterol. , 2000, Science.
[150] J. Hsuan,et al. Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. , 1999, The Biochemical journal.
[151] P. Carroll,et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. , 1996, Cancer research.
[152] J. Cutler,et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. , 1987, JAMA.
[153] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[154] A. Jemal,et al. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. , 2019, European urology.
[155] S. Freedland,et al. Words of wisdom. Re: Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. , 2013, European urology.
[156] C. Nelson,et al. Androgen‐mediated cholesterol metabolism in LNCaP and PC‐3 cell lines is regulated through two different isoforms of acyl‐coenzyme A: Cholesterol Acyltransferase (ACAT) , 2008, The Prostate.
[157] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[158] M. Freeman,et al. Cholesterol and prostate cancer , 2004, Journal of cellular biochemistry.
[159] H. Kolb,et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. , 1986, Biological chemistry Hoppe-Seyler.